- Home
- AGAE vs RPTX Comparison
AGAE vs RPTX Comparison
Compare AGAE & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- RPTX
- Stock Information
- Founded
- AGAE 2017
- RPTX 2016
- Country
- AGAE United States
- RPTX Canada
- Employees
- AGAE N/A
- RPTX N/A
- Industry
- AGAE Cable & Other Pay Television Services
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- RPTX Health Care
- Exchange
- AGAE Nasdaq
- RPTX Nasdaq
- Market Cap
- AGAE 47.2M
- RPTX 53.2M
- IPO Year
- AGAE N/A
- RPTX 2020
- Fundamental
- Price
- AGAE $1.12
- RPTX $1.12
- Analyst Decision
- AGAE
- RPTX Strong Buy
- Analyst Count
- AGAE 0
- RPTX 3
- Target Price
- AGAE N/A
- RPTX $4.50
- AVG Volume (30 Days)
- AGAE 21.9K
- RPTX 185.4K
- Earning Date
- AGAE 03-26-2025
- RPTX 03-03-2025
- Dividend Yield
- AGAE N/A
- RPTX N/A
- EPS Growth
- AGAE N/A
- RPTX N/A
- EPS
- AGAE N/A
- RPTX N/A
- Revenue
- AGAE $9,256,023.00
- RPTX $53,477,000.00
- Revenue This Year
- AGAE N/A
- RPTX N/A
- Revenue Next Year
- AGAE N/A
- RPTX $7.11
- P/E Ratio
- AGAE N/A
- RPTX N/A
- Revenue Growth
- AGAE 36.15
- RPTX 4.58
- 52 Week Low
- AGAE $0.61
- RPTX $1.06
- 52 Week High
- AGAE $1.57
- RPTX $5.66
- Technical
- Relative Strength Index (RSI)
- AGAE 61.30
- RPTX 36.62
- Support Level
- AGAE $1.00
- RPTX $1.12
- Resistance Level
- AGAE $1.10
- RPTX $1.25
- Average True Range (ATR)
- AGAE 0.06
- RPTX 0.09
- MACD
- AGAE 0.00
- RPTX -0.00
- Stochastic Oscillator
- AGAE 82.95
- RPTX 22.64
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.